Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro

  • Authors:
    • Wanhua Yang
    • Li Meng
    • Hui Wang
    • Rui Chen
    • Rui Wang
    • Xiangyi Ma
    • Gang Xu
    • Jianfeng Zhou
    • Shixuan Wang
    • Yunping Lu
    • Ding Ma
  • View Affiliations

  • Published online on: January 1, 2006     https://doi.org/10.3892/or.15.1.113
  • Pages: 113-117
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Arg-Gly-Asp (RGD) sequence was selected by using phage-display peptides to target tumors, focusing on targeting α(v) integrins in tumor blood vessels. Recent studies suggest that peptides containing the RGD sequence can bind to tumor cells, as well as tumor endothelial cells. To investigate whether the RGD peptide has other effects on tumor cells expressing α(v) integrins, besides its tumor targeting capability, we designed and synthesized a 10-amino peptide that contained the RGD sequence in a cyclic conformation with a disulfide bond, which specifically bound to breast cancer cell lines MDA-MB-231 and MCF-7. We found that this RGD peptide, GCGGRGDGGC, inhibited tumor cell proliferation in a dose-dependent manner, and also induced apoptosis and G1-phase cell cycle arrest in both of the cell lines that bound and internalized the peptide. Normal ovarian epithelial cells, which did not bind the RGD peptide, were unaffected. RGD peptide treatment also reduced cell invasiveness in both cell lines in vitro. This study suggests that the RGD peptide not only possesses tumor targeting capacity, but also has direct tumor cytotoxic and invasiveness inhibition effects dependent on the blockage of α(v) integrin activity, which would make it more efficient in tumor targeting therapy.

Related Articles

Journal Cover

January 2006
Volume 15 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang W, Meng L, Wang H, Chen R, Wang R, Ma X, Xu G, Zhou J, Wang S, Lu Y, Lu Y, et al: Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro. Oncol Rep 15: 113-117, 2006.
APA
Yang, W., Meng, L., Wang, H., Chen, R., Wang, R., Ma, X. ... Ma, D. (2006). Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro. Oncology Reports, 15, 113-117. https://doi.org/10.3892/or.15.1.113
MLA
Yang, W., Meng, L., Wang, H., Chen, R., Wang, R., Ma, X., Xu, G., Zhou, J., Wang, S., Lu, Y., Ma, D."Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro". Oncology Reports 15.1 (2006): 113-117.
Chicago
Yang, W., Meng, L., Wang, H., Chen, R., Wang, R., Ma, X., Xu, G., Zhou, J., Wang, S., Lu, Y., Ma, D."Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro". Oncology Reports 15, no. 1 (2006): 113-117. https://doi.org/10.3892/or.15.1.113